Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer

Combination versus mono-therapy as second-line treatment for advanced biliary tract cancer: a systematic review and meta-analysis of published data

(2019) Jie Ying et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Medical treatment for cholangiocarcinoma

(2019) Jorge Adeva et al.   LIVER INTERNATIONAL

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

(2019) John N Primrose et al.   LANCET ONCOLOGY

Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations

(2019) Cindy Neuzillet et al.   EUROPEAN JOURNAL OF CANCER

LBA10_PRClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation

(2019) G K Abou-Alfa et al.   ANNALS OF ONCOLOGY

LBA40FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)

(2019) A Vogel et al.   ANNALS OF ONCOLOGY

A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin

(2018) Yi Zheng et al.   BRITISH JOURNAL OF CANCER

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial

(2017) Loic Verlingue et al.   EUROPEAN JOURNAL OF CANCER

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2016) J. W. Valle et al.   ANNALS OF ONCOLOGY

Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues

(2015) Bertrand Brieau et al.   CANCER

Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma

(2015) S. Cereda et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data

(2015) Lorenzo Fornaro et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Second-line chemotherapy in advanced biliary cancer: a systematic review

(2014) A. Lamarca et al.   ANNALS OF ONCOLOGY

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer

(2014) L Fornaro et al.   BRITISH JOURNAL OF CANCER

A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer

(2013) Eiichiro Suzuki et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine

(2010) Takashi Sasaki et al.   INVESTIGATIONAL NEW DRUGS

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

S-1 Monotherapy in Patients with Advanced Biliary Tract Cancer

(2009) Takashi Sasaki et al.   ONCOLOGY